Wilke T, Neumann K, Klapper U, Messer I, Werner A, Seidel U, Röleke D
Institut für Pharmakoökonomie und Arzneimittellogistik, Hochschule Wismar, PF 1210, 23952 Wismar.
Orthopade. 2008 May;37(5):448-56. doi: 10.1007/s00132-008-1254-0.
The thrombin inhibitor dabigatranetexilat is used for prophylaxis of venous thromboembolism after total hip or knee replacement surgery (THR/TKR). Patients can take it orally in hospitals.
In a managerial pharmacoeconomic analysis of six German acute-care hospitals and six German rehabilitation hospitals, the use of dabigatranetexilat was compared with the use of low-molecular-weight heparins.
The analysis showed that the new drug led to an economic advantage for an acute-care hospital of 2.43 euro per patient per day. In a rehabilitation hospital, the use of dabigatranetexilat led to an economic advantage of 1.40 euro per patient per day.
These results have direct implications for drug decisions in hospitals. To demonstrate that fact, the price difference between dabigatranetexilat and low-molecular-weight heparins was derived to lead exactly to their"economic neutrality" from the hospital's point of view.
凝血酶抑制剂达比加群酯用于全髋关节或全膝关节置换手术（THR/TKR）后静脉血栓栓塞的预防。患者可在医院口服该药。
在对6家德国急症医院和6家德国康复医院进行的管理性药物经济学分析中，将达比加群酯的使用与低分子肝素的使用进行了比较。
分析表明，这种新药使急症医院每位患者每天获得2.43欧元的经济优势。在康复医院，使用达比加群酯使每位患者每天获得1.40欧元的经济优势。
这些结果对医院的用药决策有直接影响。为证明这一事实，从医院的角度来看，达比加群酯与低分子肝素之间的价格差异恰好导致了它们的“经济中性”。
Zotero 插件